Dariusz Woszczyk

Opole, OP, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Journal: Blood neoplasia

Published: March 20, 2026

Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Journal: Contemporary oncology (Poznan, Poland)

Published: October 16, 2025

Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative review.

Diagnosis, prognostic prediction of the accelerated phase of chronic lymphocytic leukaemia: a narrative review.

Journal: Contemporary oncology (Poznan, Poland)

Published: September 10, 2025

Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Journal: Contemporary oncology (Poznan, Poland)

Published: January 13, 2025

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age.

Journal: Cancers

Published: May 30, 2023

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.

Journal: Future oncology (London, England)

Published: November 23, 2022

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Journal: Blood advances

Published: February 15, 2022

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.

Journal: The Lancet. Infectious diseases

Published: September 20, 2018

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.

Journal: Journal of hematology

Published: February 13, 2018

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.

Journal: Leukemia

Published: November 22, 2017

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 27, 2017

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Journal: British journal of haematology

Published: May 03, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026